GLWL is conducting a Phase 2 clinical trial to to evaluate the efficacy, safety, and pharmacokinetics of GLWL-01 in treating hyperphagia in patients with PWS.
Participants will be assigned to one of two treatment sequences (GLWL-01/Placebo or Placebo/GLWL-01), with each sequence consisting of two treatment periods separated by a washout period.
This study is now recruiting patients ages 16-65 with a BMI of 27-60 kg/m2.
More information on this study is available on clincialtrials.gov or you may contact the study coordinator of your preferred site, listed below.
GLWL-01 Study Sites
Multiple study sites have been identified to date:
Rady Children’s Hospital San Diego
San Diego, California, United States, 92123
Contact: Rachel Winograd, 858-966-8453
Principal Investigator: Lynne Bird
University of Florida
Gainesville, Florida, United States, 32601
Contact: Beverly Giordano, 352-294-5280
Principal Investigator: Jennifer Miller
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Contact: Margo Black, 615-343-5846
Principal Investigator: Ashley Shoemaker
Alberta Diabetes Institute, University of Alberta
Edmonton, Alberta, Canada, T6G 2B7
Contact: Kristie Dehaan, 780-492-1095
Principal Investigator: Andrea Haqq
Montreal, Quebec, Canada, H2W 1T8
Contact: Susanne Bordeleau, 514-890-8000
Principal Investigator: Andre Lacroix
Centre Hospilaier Universitaire Ste-Justine
Montreal, Quebec, Canada, H3T 1C5
Contact: Caroline Champagne 514-345-4931 ext 6788
Principal Investigator: Cheri Deal
University Hospitals, Cleveland Medical Center
Contact: Audrey Lynn 216-844-7124, audrey.lynn@Uhhospitals.org
Principal Investigator: Shawn McCandless